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Abstract
Predictions of interactions between target proteins and potential leads are of great benefit in the drug discovery process.
We present a comprehensively applicable statistical prediction method for interactions between any proteins and chemical
compounds, which requires only protein sequence data and chemical structure data and utilizes the statistical learning
method of support vector machines. In order to realize reasonable comprehensive predictions which can involve many false
positives, we propose two approaches for reduction of false positives: (i) efficient use of multiple statistical prediction
models in the framework of two-layer SVM and (ii) reasonable design of the negative data to construct statistical prediction
models. In two-layer SVM, outputs produced by the first-layer SVM models, which are constructed with different negative
samples and reflect different aspects of classifications, are utilized as inputs to the second-layer SVM. In order to design
negative data which produce fewer false positive predictions, we iteratively construct SVM models or classification
boundaries from positive and tentative negative samples and select additional negative sample candidates according to
pre-determined rules. Moreover, in order to fully utilize the advantages of statistical learning methods, we propose a
strategy to effectively feedback experimental results to computational predictions with consideration of biological effects of
interest. We show the usefulness of our approach in predicting potential ligands binding to human androgen receptors
from more than 19 million chemical compounds and verifying these predictions by in vitro binding. Moreover, we utilize
this experimental validation as feedback to enhance subsequent computational predictions, and experimentally validate
these predictions again. This efficient procedure of the iteration of the in silico prediction and in vitro or in vivo experimental
verifications with the sufficient feedback enabled us to identify novel ligand candidates which were distant from known
ligands in the chemical space.
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Introduction
In the early stages of the drug discovery process, prediction of
the binding of a chemical compound to a specific protein can be of
great benefit in the identification of lead compounds (candidates
for a new drug). Moreover, the effective screening of potential
drug candidates at an early stage generates large cost savings at a
later stage of the overall drug discovery process.
In the field of virtual screening for the drug discovery, docking
analyses and molecular dynamics simulations have been the
principal methods used for elucidating the interactions between
proteins and small molecules [1–4]. Fast and accurate statistical
prediction methods for binding affinities of any pair of a protein
and a ligand have also been proposed for the case where
information regarding 3D structures, binding pockets and binding
affinities (e.g. pKi) for a sufficient number of pairs of proteins and
chemical compounds is available [5]. However, the requirement of
these programs for 3D structural information is a severe
disadvantage, as the availability of these data is extremely limited.
Although a number of structures in PDB [6] is increasing (from
23,642 structures in 2003 to 48,091 structures in 2007), not all
proteins which have been derived from many genome-sequencing
projects are suitable for experimental structure determination.
Hence, the genome-wide application of these methods is in fact
not feasible. For example, among the GPCRs (G-protein coupled
receptors), whose modulation underlies the actions of 30% of the
best-known commercial drugs [7], the full structure of only a few
mammalian members, including bovine rhodopsin [8] and human
beta 2 adrenoreceptor [9], is known.
To achieve more comprehensive and faster protein-chemical
interaction predictions in the post-genome era producing a vast
number of protein sequences whose structural information is not
available, it is essential to be able to utilize more readily available
biological data and more generally applicable methods which do
not require 3D structural data [10–12]. In our previous study, we
developed a comprehensively applicable statistical method for
predicting the interactions between proteins and chemical
compounds by exploiting very general biological data, including
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mass-spectrometry (MS) data [11]. These statistical approaches
provided a novel framework where the input space consists of pairs
of proteins and chemical compounds. These pairs are classified
into binding and non-binding pairs, while most chemoinformatics
approaches assess only chemical compounds and classify them
according to their pharmacological effects. Our previous study
[11] demonstrated that screening target proteins for a chemical
compound could be performed on a genome-wide scale. This is
due to the fact that our method can be applied to all proteins
whose amino acid sequences have been determined even though
the 3D structural data is not yet available. Genome-wide target
protein predictions were conducted for MDMA, or ecstasy, which
is one of the best known psychoactive drugs, from a pool of 13,487
human proteins, and known bindings of MDMA were correctly
predicted [11].
Although the method yielded a relatively high prediction
performance (more than 80% accuracy) in cross-validation and
usefulness in the comprehensive prediction of target proteins for a
given chemical compound with tens of thousands of prediction
targets [11], it suffered from the problem of predicting many false
positives when comprehensive predictions were conducted.
Although these false positives might include some unknown true
positives, they were mainly due to the low quality of the negative
data, which is one of the common problems in utilizing statistical
classification methods such as Support Vector Machines (SVMs)
and Artificial Neural Networks (ANNs).
In this paper, we describe two strategies, namely two-layer SVM
and reasonable negative data design, which are used for the
purpose of reducing the number of false positives and improving
the applicability of our method for comprehensive prediction. In
two-layer SVM, in which outputs produced by the first-layer SVM
model are utilized as inputs to the second-layer SVM, in order to
design negative data which produce fewer false positives, we
iteratively constructed SVM models or classification boundaries
and selected negative sample candidates according to pre-
determined rules. By using these two strategies, the number of
predicted candidates was reduced to around 100 (Table 1) in
experiments in which the potential ligands for some druggable
proteins (UniProt ID P10275 (androgen receptor), P11229
(muscarinic acetylcholine receptor M1) and P35367 (histamine
H1 receptor)) are predicted on the basis of more than 100,000
compounds in the PubChem Compound database (http://
pubchem.ncbi.nlm.nih.gov/).
With the aim of validating the usefulness of our method, our
proposed prediction model with fewer false positives was applied
to the PubChem Compound database in order to predict the
potential ligands for the ‘‘androgen receptor’’, which is one of the
genes responsible for prostate cancer. We verified some of these
predictions by measuring the IC50 values in an in vitro assay.
Biological experiments, conducted to verify the computational
predictions based on statistical methods, docking methods or
molecular dynamics methods, typically involve success as well as
failure. In addition to fast calculation and wide applicability, one
of the merits of using statistical methods that involve training with
known data is that results obtained by verification experiments can
be efficiently utilized as feedback to produce new and more
reliable predictions. Most previous work on virtual screening has
focused on the computational prediction and listing of dozens or
hundreds of candidates, followed by their experimental verifica-
tion. However, only on rare occasions have these experimental
results been utilized for the further improvement of computational
predictions and experiments. Moreover, even without verification
experiments, additional data acquired from, for example, relevant
literature can be used for enhancing the prediction reliability.
Therefore, we propose a strategy based on the effective
combination of computational prediction and experimental
verification. Our second computational prediction utilizing
feedback from the first experimental verification successfully
discovered novel ligands (Figure 1 and 2) for the androgen
receptor. Our approach suggests the significance of utilizing
statistical learning methods and feedback from experimental
results in drug lead discovery.
In the following section, we first describe the real application of
our method involving the computational prediction, the experi-
mental verification and the feedback, and then explain the
computational experiments conducted to verify the usefulness of
our computational prediction method in comprehensive prediction.
Results
Application of our strategy to the discovery of androgen
receptor binding ligands
First computational prediction. We set the human
androgen receptor (AR) as the target protein, whose binding
ligands were predicted by using the PubChem database. Here, AR
is a steroid hormone receptor and a transcription factor belonging
to the nuclear receptor superfamily. In pathology, AR is one of the
genes responsible for prostate cancer, which is the most frequently
diagnosed cancer in men in the United States according to the
American Cancer Society Statistics for 2008. The two-layer SVM
model with an additional model for the androgen receptor, which
constitutes a prediction model trained on the basis of
supplementary information obtained from the relevant literature
or databases as well as feedback from experimental verifications,
was applied to the screening for human androgen receptor binding
ligands from 19,171,127 chemical compounds in the PubChem
Compound database. As a result, 500 chemical compounds
(compounds with the same connectivity were counted only once)
were predicted (Figure 1A).
First experimental verification. Out of 500
computationally predicted candidates, an in vitro binding assay
Author Summary
This work describes a statistical method that identifies
chemical compounds binding to a target protein given the
sequence of the target or distinguishes proteins to which a
small molecule binds given the chemical structure of the
molecule. As our method can be utilized for virtual
screening that seeks for lead compounds in drug
discovery, we showed the usefulness of our method in
its application to the comprehensive prediction of ligands
binding to human androgen receptors and in vitro
experimental verification of its predictions. In contrast to
most previous virtual screening studies which predict
chemical compounds of interest mainly with 3D structure-
based methods and experimentally verify them, we
proposed a strategy to effectively feedback experimental
results for subsequent predictions and applied the strategy
to the second predictions followed by the second
experimental verification. This feedback strategy makes
full use of statistical learning methods and, in practical
terms, gave a ligand candidate of interest that structurally
differs from known drugs. We hope that this paper will
encourage reevaluation of statistical learning methods in
virtual screening and that the utilization of statistical
methods with efficient feedback strategies will contribute
to the acceleration of drug discovery.
Statistical Protein-Chemical Binding Prediction
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provided in Figure S4), which were chosen by considering
chemical structures and predicted probabilities from 43 chemical
compounds marked as purchasable in ChemCupid (http://www.
namiki-s.co.jp/chemcupid/) in October 2007, and there were 6
known drugs or androgens among the chosen chemical
compounds (Figure 2A). The results obtained for these 6 known
ligands agreed well with the results found in the relevant literature
[13], thus proving the reliability of the assay.
For 12 predictions, except 6 known ligands, by applying a
threshold level of IC50=100 mM, which was based on the fact that
IC50 of flutamide was more than 50 mM, a precision of 67% (4/6)
and an accuracy of 67% (8/12) were obtained (Figure 2A). As a
result, it was possible to subsequently refine the predictions by
using two misclassified compounds which were not detected in our
method but which proved to bind to the androgen receptor.
Second computational prediction with feedback. By
utilizing the results of the first experimental verification, the
prediction model was reconstructed. Although the first
computational prediction and experimental verification involved
many compounds with steroid skeletons, binding of steroid-like
compounds to the androgen receptor, which is a steroid-hormone
receptor, is relatively obvious. Moreover, since steroid-like
compounds are expected to act as agonists of the androgen
receptor, antagonists are given preference in terms of search for
chemical compounds with potential therapeutic effects for human
prostate cancer, which involves activation of the androgen
receptor. Thus, the prediction model in which pairs of the
androgen receptor and steroid-like chemical compounds were
regarded as negatives was also constructed in order to search for
antagonists of the androgen receptor. The prediction coverage of
these two models (Figure 1B and 1C) was different. The latter
prediction models predicted chemical compounds without steroid
skeletons, as expected.
Second experimental verification. Among the second
predictions, experimental verification was performed with
respect to 5 purchasable candidates, which were predicted with
the two models reconstructed with feedback data and different
strategies, as described in the previous section, and which were
selected from predictions specific to each model, including 49
compounds marked as purchasable in ChemCupid in July 2008
(details are provided in Figure S4). Out of these 5 candidates, 3
chemical compounds bound to the androgen receptor at a
threshold of 100 mM (Figure 2B), thus achieving 60% precision
(3/5).
As shown in Figure 2C, known drugs and chemical compounds
in the additional data can be roughly divided into two regions in
the chemical space, which is based on the results of the Principal
Component Analysis (PCA) applied to known ligands and
chemical compounds in additional data represented by E-Dragon
Table 1. Evaluation of our method with respect to comprehensive interaction prediction.
dataset
1 neg.
2 1sts
3 P10275
4 P11229
4 P35367
4 rec0.5 (%)
5 rec0.95 (%)
5 evaluation
6
(A)
mlt 16 – 714 1408 1187 100 98.97 82.50
random 16 – 1869.3(6136.1) 10503.3(61250.7) 9305.3(6517.8) 100 99.66(61.09) 69.45(60.32)
(B)
mlt 14 10 177 535 451 96.91 93.81 75.56
random 14 10 848.3(6345.0) 1531.7(6628.9) 988.0(6411.4) 96.56(62.89) 81.10(619.44) 66.44(67.82)
(C)
max 16 9 28 231 129 100 97.94 82.92
random 16 9 74.7(642.6) 255.3(632.2) 146.7(68.3) 100 100 80.67(60.93)
(D)
– – – 640 1791 838 86.60 71.13 59.66
(E)
– – – 1869 1816 1580 – – –
(A) One-layer SVM. (B) Two-layer SVM with the first-layer SVM models based on the subpos datasets. (C) Two-layer SVM with the first-layer SVM models based on the
allpos datasets. (D)
{SVM only utilizing chemical compound information. (E)
{Similarity search.
{SVM model which only classifies chemical compounds (not pairs) according to the binding property to the target proteins. Chemical compounds binding to each
target protein were treated as positives, and all other compounds in the DrugBank dataset were regarded as negatives.
{A chemical compound i was predicted as binding to a protein a by using the similarity method if predsim i ðÞ ~maxj[A I\J jj = I|J jj §0:9, where A represents the known
binding ligands of a,a n dI (or J) represents a set of substructures considered in calculating the feature vector of the chemical compounds.
1refers to negative data expansion rules (details are provided in Materials and Methods). ‘‘random’’ indicates that three types of random pairs comprising a protein and a
drug are used as negatives. The 95% confidence intervals are shown.
2the number of negatives (=1,7506x).
3the number of first-layer SVM models utilized to construct the second-layer SVM model.
4target proteins whose ligands were predicted from 109,841 compounds. The number of predicted ligands is shown.
5recx is the recall rate(=TP/(TP+FN)) at the threshold x. 0.5 is the threshold following the definition of SVM. TP: true positives, FN: false negatives.
6
evaluation~100|
1
2
rec0:5z
rec0:95zprec0:95
21 z 1{rec0:95 ðÞ 1{prec0:95 ðÞ fg
  
{
total # of predicted positives   # of known positives
total # of predicted targets   # of known positives
   
ð1Þ
Here, precx is the precision (=TP/(TP+FP)) at the threshold x. FP: false positives.
doi:10.1371/journal.pcbi.1000397.t001
Statistical Protein-Chemical Binding Prediction
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tional prediction belonged to one of these regions, T5853872
(Figure 2C and 2D), which is one of the second computational
predictions based on the designed strategy, was not included in
these regions. This result suggests that repeating the processes of
the computational prediction, the experimental verification and
the feedback of the experimental results for new predictions
contributes to the efficient exploration of the chemical space
targeted in the search as well as to the discovery of novel ligands.
The third computational prediction, which utilized the results of
the second experimental verification, further extended the
predictions (details are provided in Text S1 and Figure S5) and
successfully predicted chemical compounds which were of
structural variety (data not shown). The repetition of the process
of integrating computational prediction and experimental verifi-
cation continues to provide novel candidates.
Indication of the biological validity of statistical
approaches
In bioinformatics, statistical approaches extract rules from
numerical data corresponding to biological properties. Here, it is
not guaranteed that the extracted rules are biologically valid, and
furthermore it is possible to utilize statistical methods to obtain
general rules from any kind of numerical data which are
meaningless and irrelevant to biological properties. The biological
relevance of our approach can be verified as follows on the basis of
supporting evidence which indicates that our method can extract
significant rules only if biologically valid and relevant data is given.
First, high prediction performances on diverse datasets might
support the validity of our approach. In several datasets consisting
of known pairs of proteins, including nuclear receptors, GPCRs,
ion channels and enzymes, and drugs and random protein-drug
pairs, our statistical approach with SVM showed high prediction
performances (details are provided in Text S1, Table S1 and
Figure S2). The fact that more than 0.85 AUC and an accuracy of
80% were obtained for diverse datasets suggests that it is possible
to extract some properties accountable for interactions between
proteins and drugs by statistical approaches. This possibility can be
further supported by the fact that integrating several datasets
whose target proteins were not relevant to each other improved
the prediction performances with respect to pairs of proteins and
chemical compounds which had a specific binding mode (details
are provided in Text S1 and Table S2).
Second, we showed the biological relevance of these high
prediction performances by calculating the prediction perfor-
mances using biologically meaningless artificial datasets as
positives. Several datasets which contained fractions of valid
samples found in the DrugBank dataset, and which comprised
artificial pseudo-positive samples of protein-chemical pairs pro-
duced by shuffling with the same frequency of chemical
compounds and proteins as that in the DrugBank dataset, were
generated. Our method was applied to these shuffled artificial
datasets (Figure 3). Here, if our approach did not depend on the
biological properties of the given dataset but only succeeded in
classifying given pairs comprising a protein and a chemical
compound and random pairs derived from them, the prediction
accuracy for each shuffled dataset was assumed not to fluctuate.
As shown in Figure 3, the prediction accuracy was proportional
to the content rate of the biologically valid samples. Therefore, the
classification of our approach was shown to function only when a
certain amount of biologically valid pairs comprising a protein and
a chemical compound are given. This result suggests that our
statistical approach succeeds in extracting the rules which are only
relevant for the biological binding properties.
False positive reduction in comprehensive prediction
It is often observed that although statistical learning approaches
achieve very high prediction performances in given datasets,
statistical prediction models suffer from the problem of generating
vast prediction sets including many false positives when applied to
a huge dataset, such as the PubChem database. In our approach,
SVM models based on feature vectors directly representing amino
acid sequences, chemical structures, and random protein-com-
pound pairs as negatives also produced many predictions and
inevitably yielded many false positives (Table 1A random).
Upon the introduction of the two-layer SVM and the negatives
designed to overcome this drawback, the prediction precision, or
the confidence of positive prediction, was significantly improved in
computational experiments based on the DrugBank dataset
(Table 2). In Table 2, the external dataset consisted of 170
positives and 2,450 negatives that were randomly chosen from
1,731 positives and 24,500 designed negatives with the mlt rule
(details are provided in Materials and Methods) and that were
excluded in constructing first-layer and second-layer SVM models.
The external dataset contained much more negatives than
positives as it simulated the real application of virtual screening
with vast databases where only a fraction of chemical compounds
in the databases have the effect of interest. Tables 2A and 2B
showed improvement of precision by introducing the designed
negatives and the two-layer SVM respectively. Table 2B also
indicated that the application of SVM to outputs of the first-layer
SVM models was superior to other statistical learning methods
[15] and naive combination of the first-layer SVM models, and
that rational selection of the first-layer SVM models achieved
Figure 1. The scope of the predictions changed depending on
whether feedback data were used and how they were utilized.
(A) 500 predictions without feedback data. (B) 527 predictions with
feedback from the first experimental verification. (C) 213 predictions
based on the feedback strategy where pairs of chemical compounds
with steroid structures and the androgen receptor were regarded as
negatives.
doi:10.1371/journal.pcbi.1000397.g001
Statistical Protein-Chemical Binding Prediction
PLoS Computational Biology | www.ploscompbiol.org 4 June 2009 | Volume 5 | Issue 6 | e1000397Figure 2. The first and the second experimental verifications showed more than 60% accuracy of computational predictions and
the chemical space of verified compounds was explored. (A) Results of the first in vitro binding assay. (B) Results of the second in vitro
binding assay. (C) The chemical space based on E-Dragon [14] descriptors and the principal component analysis (PCA) applied to known ligands and
additional data. The black squares correspond to known ligands in the training data, the solid black squares represent known approved drugs, the
blue triangles correspond to true positives in the first computational prediction, and the red diamonds correspond to true positives in the second
computational prediction. The open red diamonds belong to Figure 1B, and the solid red diamonds belong to Figure 1C. Chemical compounds
located between the two dashed lines have steroid-like structures. (D) A potential ligand with a chemical structure differing from the structures of
known ligands. In (A) and (B),
1; PubChem Compound ID.
2; computational prediction expressed as ‘‘label (predicted probability for a positive
outcome)’’.
3; The concentration of an unlabeled test compound, in which, according to the measured radioactivity, 50% of the [
3H]-DHT is still bound
to MBP-ARC.
4; chemical compounds included in the DrugBank set or additional data.
B (C); predictions belonging to Figure 1B (C).
doi:10.1371/journal.pcbi.1000397.g002
Figure 3. The prediction accuracy is proportional to the content rate of biologically valid samples. The average of 10 datasets produced
by shuffling pairs corresponded to each content rate (ex. 50%) of pairs comprising a protein and a chemical compound in the original dataset. A usual
SVM training, which is referred to as the first-layer SVM in the Materials and Methods section, and a 10-fold cross-validation evaluation were
performed for each dataset of 1,731 positives and 1,750 negatives (or random pairs other than positives). Here, the SVM parameters were selected in
such a way that they gave the best accuracy.
doi:10.1371/journal.pcbi.1000397.g003
Statistical Protein-Chemical Binding Prediction
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randomly selected models (other comparisons are provided in
Text S1, Table S3 and Table S4). Particularly, the second-layer
SVM utilizing the allpos first-layer SVM models achieved higher
precision than use of higher thresholds in the other SVM models
(Table 2C). The high precision contributes to the selection of more
reliable predictions and thus to the reduction of the number of
false positives.
Following these results on given datasets, our approaches were
evaluated with respect to comprehensive binding ligand predic-
tion. For three proteins (UniProt ID P10275 (androgen receptor),
P11299 (muscarinic acetylcholine receptor M1) and P35367
(histamine H1 receptor)), their binding ligands were predicted
from PubChem Compound 0000001–00125000 which contains
109,841 compounds (Table 1). Here, P35367 and P11299 are the
two most frequently targeted proteins in the DrugBank dataset,
and P10275 is a protein of average occurrence in the DrugBank
dataset. Among the 109,841 compounds, 47, 45, and 5 known
ligands were included for P35367, P11299, and P10275,
respectively.
As shown in Tables 1A, 1B and 1C, the use of carefully selected
negatives, the introduction of the two-layer SVM, and the
integration of these two approaches efficiently reduced the number
of predictions and thus the number of false positives. For example,
in comparison to Tables 1A and 1C, the number of candidates
discovered by using the max dataset in the allpos two-layer SVM
approach was about one fiftieth of the number of chemical
compounds predicted by using the random negative dataset in the
one-layer SVM. Furthermore, in comparison to other approaches
based solely on the use of chemical compounds (Tables 1D and
1E), our approaches gave a reasonable number of predictions
(other comparisons are described in Text S1 and Tables S5, S6,
S7).
These results suggest that our prediction models select a
reasonable number of ligand candidates from all chemical
compounds in large databases and encourage the comprehensive
binding ligand prediction for the target protein.
Utilization of feedback and additional data
The experimental verification of the computational predictions
produces feedback data or samples which are not included in the
given training datasets. The efficient utilization of these data can
contribute to the fast identification of compounds with the desired
properties and can be of advantage to statistical learning
approaches.
We compared several strategies for utilizing feedback data as
follows. For three proteins (UniProt ID P10275 (androgen
receptor), P11299 (muscarinic acetylcholine receptor M1) and
P353367 (histamine H1 receptor)), ligand data which were not
included in the DrugBank dataset were collected from relevant
literature [16–18] and public databases, PDSP Ki database [19]
and GLIDA [20], in February 2008. Overall, 35 androgen
Table 2. Evaluation of our method with respect to internal and external prediction of the dataset.
Model type
{ prec.
in (%)
{ sens.
in (%)
{ acc.
in (%)
{ prec.
ex (%)
{ sens.
ex (%)
{ acc.
ex (%)
{
(A)
one-layer(designed) 71.76 42.99 95.11 64.66 50.59 95.00
one-layer(random) 82.38(60.64) 38.22(60.95) 95.38(60.06) 40.68(61.19) 50.00(61.87) 92.02(60.28)
(B)
subpos 97.11 92.57 99.33 82.81 31.18 95.11
subpos(r.f.) 95.66(60.32) 78.33(61.60) 98.33(60.10) 78.76(62.86) 25.59(61.09) 94.71(60.09)
voting ---8 . 8 9 5 7 . 0 6 5 9 . 2 7
2
nd ANN 95.98 93.21 99.29 75.81 27.65 94.73
2
nd QDA 70.69 54.39 95.49 34.52 17.06 92.52
(C)
allpos 99.68 100.00 99.98 100.00 10.59 94.20
subpos(t= 0 . 9 )---9 0 . 7 0 2 2 . 9 4 9 4 . 8 5
one-layer(t= 0 . 9 ) ---8 6 . 6 7 1 5 . 2 9 9 4 . 3 5
(A) Effect of rational negative design. (B) Effect of the second-layer SVM with designed negatives. (C) Improvement of precision with the two-layer SVM ant the type of
the first-layer SVM models.
{‘‘Model type’’ exhibits the one-layer SVM model or the second-layer SVM, which is specified by the type of 11 first-layer SVM model, was utilized. Here,
N (designed) means that the rationally designed negatives was used to construct the SVM model.
N (random) means that three types of randomly chosen 22,050 pairs of protein and chemical compounds were used use to construct the SVM model. The 95%
confidence intervals were shown.
N (r.f.) means that twenty types of randomly chosen 11 first-layer SVM models were used to construct the second-layer SVM model.
N 2
nd ANN means that Artificial Neural Network (ANN; implemented by the statistical software package R (http://cran.r-project.org/) function nnet [15]) was applied to
outputs of 11 subpos first-layer SVM models. Parameters were selected to give the best accuracy in internal 10-fold cross validation. For example, 17 units were used in
the hidden layer.
N voting means that voting with 11 subpos first-layer SVM models was used for prediction.
N 2
nd QDA means that Quadratic Discriminant Analysis (QDA) (implemented by R function qda [15]) was applied to outputs of 11 subpos first-layer SVM models.
N (t=0.9) means that final probability outputs were evaluated with the threshold t=0.9.
{precision (prec.)=TP/(TP+FP), sensitivity (sens.)=TP/(TP+FN), accuracy (acc.)=(TP+TN)/(TP+FN+TN+FP). TN: true negatives. Here,
N
ex means the prediction performances of the external prediction. The external dataset consisted of 170 positives and 2,450 negatives that were randomly chosen from
1,731 positives and 24,500 designed negatives with the mlt rule (details are provided in Materials and Methods) and that were excluded in constructing first-layer and
second-layer SVM models.
N
in means the prediction performances of internal 10-fold cross-validation. The internal dataset utilized 1,561 positives and 22,050 negatives, which were not included in
the external dataset.
doi:10.1371/journal.pcbi.1000397.t002
Statistical Protein-Chemical Binding Prediction
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ligand pairs, and 1,060 histamine H1 receptor-ligand pairs were
supplemented. Additional models were constructed by using these
supplemental pairs as positives (details are provided in Text S1).
As shown in Figure 4, the use of the additional model with a
sufficient weighting factor controlled the increase of the predic-
tions with a slight decrease of the recall rate. The use of large
weighting factors results in the relative decrease of the influence of
other first-layer SVM models derived from the DrugBank dataset
in classification. However, the low performance of ‘‘only
additional model:st2’’, shown in Figure 4A, where only one first-
layer SVM model derived from additional data was used to
construct the second-layer SVM model, indicates the need for
first-layer SVM models derived from the DrugBank dataset as well
as combinations of these first-layer SVM models with an
additional first-layer SVM model.
With this efficient strategy for utilizing feedback data,
computational prediction and experimental verification improve
each other to enable faster search toward the identification of
useful small molecules.
Discussion
We proposed a comprehensively applicable computational
method for predicting the interactions between proteins and
chemical compounds, in which the number of false positives was
reduced in comparison to other methods. Furthermore, we
proposed the strategy for the efficient utilization of experimental
feedback and the integration of computational prediction and
experimental verification.
The application of our method to the androgen receptor
resulted in 67% (4/6) prediction precision according to in vitro
experimental verification in the first computational prediction and
60% (3/5) in the second prediction, which included the feedback
of the first experimental verification. However, these relatively low
precision values do not represent the true statistical significance of
the method.
This 60–70% precision can also be evaluated by using the
following P-value.
P{value~
X t
x~p
MCx| N{M ðÞ C t{x ðÞ
NCt
Here, N is the number of prediction targets, M the number of
ligands potentially binding to the target proteins, t is the number of
tested compounds, and p is the number of true positives. With
N=19171127, which is the number of chemical compounds in the
PubChem Compound database, and M=191711276(456/
3000)6(7/964)V21160, which is based on the optimistic assump-
Figure 4. Effects of the strategy for the utilization of feedback and additional data. (A)
1: st1; a strategy where additional data, or pairs
comprising a chemical compound and a protein, were simply added to the training samples in constructing a prediction model. st2; a strategy where
additional data were first used for the construction of an additional first-layer SVM model and subsequently added to the training samples in the
construction of a second-layer SVM model.
2: target proteins whose ligands were predicted from 109,841 compounds. The number of predicted
ligands is shown.
3: one-layer SVM using the mlt dataset with 28,000 negatives.
4: two-layer SVM using 9 allpos first-layer SVM models and the max
dataset with 28,000 negatives. In st2, the weighting factor was set to 50.
5: SVM model where the chemical compounds binding to each target protein
were treated as positives, and all other compounds in the DrugBank dataset were regarded as negatives.
6: SVM model where pairs of all target
proteins and known ligands were treated as positives, while pairs of all target proteins with other compounds were regarded as negatives.
7: two-
layer SVM model in which only one first-layer SVM model derived from additional data was used for the construction of a second-layer SVM model.
*:
a threshold of 0.9 was used instead of 0.95 for the calculation of ‘‘evaluation’’ (Eq. (1)). (B) The relation between the weighting factors and the number
of predictions is shown for the case where the threshold=0.5.
doi:10.1371/journal.pcbi.1000397.g004
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some target protein, it is estimated that 3,000 druggable proteins
exist [21]. Moreover, the distribution of target proteins and drugs
in the DrugBank dataset, consisting of 456 target proteins and 964
drugs, including 7 known ligands for the human androgen
receptor, and P-values of 2:21610
211 and 1:34610
28 are
obtained for the prediction precision of the first and the second
computational prediction, respectively. These extremely small P-
values prove the significance of the virtual screening and its
precision in the drug discovery process.
These prediction performances are as good as or better than
several previous virtual screening studies based mainly on docking
analyses [22–24]. For example, at a threshold of 100 mM, 7%
precision (3/39) for Mycobacterium tuberculosis adenosine 59-phos-
phosulfate reductase [22], 71% precision (22/31) for Staphylococcus
aureus methyonyl-tRNA synthetase [23] and 8% precision (16/192)
for human DNA ligase I [24] were obtained, respectively. In
addition, 0.566 AUC was achieved in the docking analysis using
AutoDock [3] (Figure 5) for the 17 chemical compounds (12
chemical compounds verified in the first experimental verification,
with the exception of 6 known drugs, and 5 chemical compounds
verified in the second experimental verification). In contrast, 0.681
AUC was obtained with our method. Here, in the calculation of
AUC, the threshold level of IC50=100 mM for experimental
verification was used to define a label (binding or non-binding) for
each chemical compound, and {log Estimated Ki ðÞ or the
predicted probability was regarded as a value for each molecule.
Note that the docking analysis with AutoDock was not applied to
the 19,171,127 compounds in the PubChem Compound database
for the screening purpose, but was applied only to 17 compounds,
which were the results of virtual screening by our method. In terms
of computational time, for binding prediction of one pair of a
protein and a chemical compound, using one Opteron 275
2.2 GHz CPU, AutoDock took approximately 100 minutes on
average with 100 genetic algorithm (GA) runs, while our method
required less than 0.3 seconds. These computational time
comparisons indicate that our method can perform a virtual
screening of more than 19 million chemical compounds from the
PubChem Compound database for any proteins in genome-wide
scale and this immense screening task would be infeasible to
accomplish with any of the existing docking methods. Therefore,
our statistical approach can contribute as the first fast and rather
accurate virtual screening tool for the drug discovery process. It
can be followed by the application of more time-consuming but
more informative approaches, such as docking analysis and
molecular dynamics analysis, which can provide information
regarding the binding affinities and the molecular binding
mechanisms to outputs of the first screening.
In another perspective, the re-evaluation of statistical prediction
approaches by using 23 chemical compounds experimentally
verified in this study showed that our proposed methods, which
utilized information of both protein sequence and chemical
structures, were superior to a conventional LBVS (Ligand Based
Virtual Screening) method where only structures of specific
Figure 5. Docking analyses of experimentally verified chemical compounds. The blue circles denote known compounds and the red
triangles denote other tested compounds. {log Estimated Ki ðÞ was derived from the estimated inhibition constant of the first cluster in the
AutoDock output. Also, the horizontal dotted line denotes the threshold of 100 mM and the vertical dashed line denotes the threshold of 300 nM,
which is based on the estimated Ki 210.27 nM of flutamide, a known drug. With this threshold, 59% accuracy (10/17) and 57\% precision (8/14) were
achieved while our method obtained an overall 65% accuracy (11/17; 8/12 in the first experimental verification and 3/5 in the second experimental
verification) and 64% precision (7/11; 4/6 in the first experimental verification and 3/5 in the second experimental verification).
doi:10.1371/journal.pcbi.1000397.g005
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Figure 6A, our proposed methods (‘‘one-layer SVM’’, ‘‘two-layer
SVM-subpos’’ and ‘‘two-layer SVM-allpos’’) achieved a higher recall
rate at ranks higher than 500 compared to a conventional Ligand
Based Virtual Screening method (‘‘only compound SVM’’ in
Figure 6A). The fact that experimentally verified chemical
compounds were identified at higher ranks in the pool by our
proposed prediction models suggests that our proposed models
were highly efficient with respect to the screening method.
Figure 6B also shows that our proposed methods were more
successful at discriminating between 15 experimentally verified
binding and 8 non-binding ligands better than the LBVS method.
These comparisons suggest that our proposed method utilizing
information of protein sequences as well as chemical structures can
be regarded as a more useful substitute for usual ligand-based
virtual screening methods utilizing only chemical structures.
Furthermore, the fact that the second computational prediction,
or the use of feedback data, contributed to the discovery of novel
ligands (Figure 2B–D) supports the utilization of statistical learning
methods in virtual screening.
Regarding the computational prediction method used in this
paper, we made the method available to the public as a web-based
service named COPICAT (COmprehensive Predictor of Interac-
tions between Chemical compounds And Target proteins; http://
copicat.dna.bio.keio.ac.jp/).
Materials and Methods
Experimental datasets
The DrugBank dataset was constructed from Approved
DrugCards data, which were downloaded in February, 2007 from
the DrugBank database [25]. These data consist of 964 approved
drugs and their 456 associated target proteins, constituting 1,731
interacting pairs or positives.
Computational prediction
Support vector machines. Given n samples, each of which
has an m-dimensional feature vector (xi~ x1
i ,   ,xm
i
  
) and one of
two classes, such as binding and non-binding (yi[ 1,{1 fg ), an
SVM produces the classifier
fx ðÞ ~sign
X n
i~1
aiyiKx i,x ðÞ zb
 !
, ð2Þ
where x is any new object which needs to be classified, K :,: ðÞ is a
kernel function which indicates that the similarity between two
vectors and (a1,...,an) are the learned parameters [26]. The
output of an SVM can be regarded as a probability [27].
First-layer SVM. In the first-layer SVM, a pair comprising a
protein and a small molecule, which constitutes a sample, is
Figure 6. Re-evaluation of our method using the data of experimentally verified chemical compounds. (A) Evaluation by recall rate with
10,000 chemical compounds. Here, the recall rate at the rank x in descending order of predicted binding probability was calculated as (the number of
15 binding ligands whose rank is higher than x)/15. The 10,000 tested chemical compounds included 1,041 predicted ligand candidates, as shown in
Figure 1, and 8,959 of the compounds were found within PubChem Compound CID 1-10427. (B) AUC using the data of 15 experimentally verified
ligands and 8 non-binding chemical compounds.
*: In both (A) and (B), the prediction models were constructed as described in Figure 4, where 6
known chemical compound-androgen receptor pairs or 6 known chemical compounds among the 23 verified chemical compounds were excluded
from the dataset utilized to construct the final prediction model and the weighting factor for two-layer SVM models was set to 10.
doi:10.1371/journal.pcbi.1000397.g006
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space by using amino acid sequences for proteins and 2D chemical
structures for chemical compounds. Details regarding the
numerical representation of the proteins and the chemical
compounds are described in Text S1.
We generated 100 first-layer SVM models with different
random combinations of proteins and chemical compounds as
negatives. The SVM parameters were chosen to give the best
accuracy in a 10-fold cross validation in one set of positives and
negatives.
We prepared two sets of first-layer SVM models, each of which
consists of 100 models. One set allpos contains the SVM models
constructed from 1,731 positives, or the whole DrugBank dataset,
and 1,750 negatives. The other set subpos is composed of models
with 534 positives, one of 10 kinds of DrugBank subsets, and 550
negatives. A protein found n times in the DrugBank dataset is
designed to appear
& n/10
& +1 times in a DrugBank subset, and
the chemical compounds with which the protein forms a pair differ
between different subsets.
Second-layer SVM. The second-layer SVM directly utilizes
the outputs of the first-layer SVM models as inputs. The second-
layer SVM model was constructed from the whole DrugBank
dataset and reasonably designed negatives, which are described in
detail later, on the basis of the RBF kernel
Kx ,y ðÞ ~exp {c x{y kk
2
  
in Eq. (2). The SVM parameters
were selected in such a way that they gave the best accuracy in the
10-fold cross validation. A schematic illustration of the second-
layer SVM is shown in Figure S1.
Feature selection. The number of first-layer SVM models
whose output is used in the second-layer SVM models mainly
determines the computation time and the workload of the two-
layer SVM methods. Therefore, in order to practically realize
comprehensive protein-chemical interaction predictions, fewer
first-layer models achieving high prediction accuracy are given
preference.
We applied the recursive feature elimination (RFE) method [28]
in order to determine the first-layer SVM models used to construct
the second-layer SVM model. Details are shown in Text S1 and
Figure S3.
Negative data design. We followed and modified the
method described in Wang et al., 2006 [29] for the design of
negative data leading to the reduction of the number of false
positives. First, negative seeds were selected on the basis of the
distances between positive samples and unspecified samples, or
between all combinations of proteins and chemical compounds in
the dataset other than positives. Second, the negative samples were
extended sequentially according to the four expansion rules min,
mlt, mle and max by using the outputs of the prediction model
constructed from positive samples and tentative negative samples
as follows,
N min: Top L samples in the ascending order of pi, iMU-N
N max: Top L samples in the descending order of pi, iMU-N
N mle: Top L samples in the descending order of pi, iMU-N s.t.
pi#0.5
N mlt: Top L samples in the descending order of pi, iMU-N s.t.
pi,0.5
where N was a set of tentative negative samples, U was a set of
all the possible combination of combinations of proteins and
chemical compounds in the dataset except positive samples, and pi
was a probabilistic output of SVM. More details are provided in
Text S1.
Experimental verification
Materials. Unless otherwise specified, all solvents and
reagents were obtained from commercial suppliers.
In the plasmid preparation, pTriAR, a construct in which
Androgen receptor (AR) cDNA is subcloned into the pTriEX-3
Neo vector, was provided by Taiho Pharmaceutical.
In the in vitro binding assay, dihydrotestosterone (DHT),
flutamide, nilutamide, spironolactone and cortexolone were
purchased from Sigma. Testosterone and bicalutamide were
purchased from Wako Pure Chemical Industries. ZINC
04369595, MDPI 944, MDPI 1011, NSC 6129, MDPI 10314,
3-epiuzarigenin, ZINC 04026296, methandriol, vitamin D3,
ZINC 03849821, P712100 and fluanisone were purchased from
Namiki Shoji.
Preparation of MBP-ARC (Maltose Binding Protein
tagged Androgen Receptor C-termini). The gene sequences
corresponding to the ligand-binding domain (609th a.a.–919th
a.a.) of androgen receptor C-termini (ARC) were subcloned into
pMALc-2x vector digested with HindIII and BamHI, and the
maltose binding protein-fusion androgen receptor C-termini
(MBP-ARC) was expressed in E. coli DH5a, and purified on
amylose resin (BioLabs). Details are provided in Text S1.
Here, it is reported that an in vitro binding assay with ARC
producedalmostthesameresultsasthatwithwhole-lengthAR[30].
The in vitro binding assay - hydroxyapatite
method. 50 mg/ml MBP-ARC, 2 nM [
3H]-DHT, and the
indicated amount of test compounds were incubated for three
hours. Then, the radioactivity of [
3H]-DHT bound to MBP-ARC
was measured with a scintillation counter. Details are provided in
Text S1.
The concentration of the test compound to [
3H]-DHT in which
the measured radioactivity corresponded to 50% of that measured
without the test compounds was regarded as IC50 of the test
compound.
Feedback strategy
Given Np positive and Nn negative samples in known data and
Mp positives and Mn negatives in additional or feedback data, a
straightforward strategy for the integration of additional data into
statistical training, such as SVM, is to train a statistical model
based on a dataset consisting of Np+Mp positives and Nn+Mn
negatives. When the two-layer SVM strategy is applied, another
strategy of feedback and supplement involves the utilization of an
additional model based on additional data. In this strategy, the
second-layer SVM is trained on the basis of Np+Mp positives and
Nn+Mn negatives, and a sample si in the second layer is represented
as follows,
si~ w|pa
i ,p1
i ,...pk
i
  
:
Here, pa
i is an output of the additional model trained on the basis
of Mp positives and Mn negatives. p
j
i is an output of the first-layer
SVM model j, and w is a weighting factor.
Docking analysis
AutoDock 4 [3] was applied to the human androgen receptor
ligand-binding domain (PDB code; 2AM9 [31]) and tested
compounds whose 3D structure was generated by Obgen in the
Open Babel package ver.2.2.0 [32] or CORINA [33]. The
conditions of AutoDock followed Jenwitheesuk and Samudrala,
2005 [34]. ARG752 of 2AM9, which was considered important
for the binding of androgens by the human androgen receptor
[31], was set to a flexible residue in AutoDock.
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